A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma.

erastin - Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Columbia University, Prolexys

A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma. (PubMed, Discov Oncol) - Feb 12, 2025 - "Our study highlights the potential of the FRLs signature as a prognostic tool and its implications for therapeutic strategies in MM."
Journal • Hematological Malignancies • Multiple Myeloma • Oncology • DIRC1

http://www.ncbi.nlm.nih.gov/pubmed/39934434

Jialin Tang; Jianbin Chen; Wei Yu; Zizi Jing

Feb 12, 2025